title: Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance.
authors.forename: William T
authors.initials: WT
authors.lastname: Cefalu
authors.forename: Julio
authors.initials: J
authors.lastname: Rosenstock
authors.forename: Robert R
authors.initials: RR
authors.lastname: Henry
authors.forename: Matthew
authors.initials: M
authors.lastname: Riddle
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D006801:Humans; D054795:Incretins / Q000009:adverse effects* / Q000627:therapeutic use; D060735:Pharmacovigilance
chemical_list: D054795:Incretins